Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
    • What are Neuroendocrine Cancers?
    • What are Pheos & Paras?
    • NET Symptoms
    • NET Types
    • Causes
    • Treatments
    • Grades
    • Diagnosis
    • Prognosis
    Consider the Grey Area
  • Patients & Carers
    • Patient & Carer Support
    • Patient Resources
    • Optimal Care Pathway
    • NET Nurse
    • Patient Stories
    • Share your Story
    • Australian NET Specialists
    • Clinical Trials
    • Living with NETS
    • Specialist Support Services
    Consider the Grey Area
  • Healthcare Professionals
    • Optimal Care Pathway
    • Professional Learning
    • Patient Referral
    • Clinical Trials
    • NET Symptoms
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order Booklets & Resources
    Consider the Grey Area
  • Get Involved
    • Advocate for Us
    • Share your Story
    • Donate
    • Fundraise
    • Events
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Volunteer
    Senate MailChimp
  • March4NETs
NET Nurse
Donate

Home » Research » Theranostics World Congress 2016

Theranostics World Congress 2016

  • February 10, 2016
We warmly invite you to join us in Melbourne for the 4th Annual Theranostics World Congress from November 7-9 2016. Registrations open 19 Feburary 2016.
 
 
The purpose of this conference is to educate, promote, and support the application and use of radio-labelled agents in the diagnosis and treatment of cancer. Building on principles first established using radio-iodine for imaging and treatment of thyroid cancer, theranostics is entering an exciting phase of its evolution with new targets being identified and increasing evidence of the success and wider applicability of this approach.
 
The theme for 2016 is “If you can see it, you can treat it”
 
The conference will feature invited and contributed presentations on molecular imaging tracers that allow selection and prediction of response to radionuclide therapies as well as the latest information on radionuclide therapy trials.
 
The disease focus will be neuroendocrine tumours and prostate cancer with exciting and innovative theranostic advances being presented from around the globe. Updates on somatostatin receptor imaging and Peptide Receptor Radionuclide Therapy (PRRT) of neuroendocrine tumours and PSMA imaging and therapy of prostate cancer will be of particular interest to clinicians working with these diseases. Public forums are planned to provide information and answer questions that patients and their families may have about these therapies.
 
We anticipate a diverse group of participants and speakers representing the entire range of translational and clinical theranostics. For radiochemists, physicists and scientists, new ligands and targeting vectors, advances in post-processing and dosimetry methods, and translational research on innovative theranostics, will also be featured. 
 
A pre-congress symposium will take place on Sunday November 6 in the new home of the Peter MacCallum Cancer Centre, a $1 billion building as part of the Victorian Comprehensive Cancer Centre Project. In celebration of 20 years of PET and PRRT at Peter Mac, this symposium will look back on the evolution of these technologies through to the current day and also look forward to what is on the horizon. We expect this will provide a tasty appetizer to the main congress and provide an opportunity to visit what will become an iconic building in Melbourne. Early registration of interest in this pre-congress is encouraged as there will be strictly limited numbers.
 
Marvellous Melbourne has many nearby attractions and exciting events, especially in November, so please join us in the “World’s Most Liveable City”, for a stimulating scientific programme and the opportunity to meet opinion-leaders in the field.
 
Simone Leyden                                  Professor Rodney J.Hicks
CEO Unicorn Foundation                  MBBS (Hons), MD, MD, FRACP, FAHMS
Theranostics Convenor 2016            Chair, Congress

Share this post

Recent posts

VHL Awareness Month 2025

May 6, 2025

NET Patient Chris, from Ballarat, Raises Awareness of Neuroendocrine Cancer

May 5, 2025

Help Us Grow: Connect NECA with Corporate Partners to Make a Lasting Impact

April 29, 2025

Neuroendocrine Cancer Awareness Daily Mail 5 April 2025

April 5, 2025
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousProfessor Rod Hicks inducted into the Australian Academy of Health and Medical Sciences
NextMonthly NET Cancer Research UpdateNext

Related Posts

NECA at ENETS 2025: Advancing NET Care on the Global Stage

NeuroEndocrine Cancer Australia at ENETS 2025: Advancing NET Care on the Global Stage NeuroEndocrine Cancer Australia (NECA) proudly represented Australia at the 22nd Annual European

The Australian Cancer Plan

Shaping the future of cancer control together   We are pleased to send you this update on the Australian Cancer Plan, the first national 10-year

Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness

Read full report

Peter MacCallum Cancer Centre – Recruiting NET health professionals for International Delphi survey

Recruiting NET health professionals for International Delphi survey Development of a neuroendocrine tumour (NET) nutrition-risk screening tool to identify patients requiring nutrition intervention and education

View All

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Patients & Carers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

Healthcare Professionals

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2025 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin